JP2025521084A5 - - Google Patents

Info

Publication number
JP2025521084A5
JP2025521084A5 JP2024566249A JP2024566249A JP2025521084A5 JP 2025521084 A5 JP2025521084 A5 JP 2025521084A5 JP 2024566249 A JP2024566249 A JP 2024566249A JP 2024566249 A JP2024566249 A JP 2024566249A JP 2025521084 A5 JP2025521084 A5 JP 2025521084A5
Authority
JP
Japan
Prior art keywords
recombinant polypeptide
domain
polypeptide according
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025521084A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/021652 external-priority patent/WO2023220118A2/en
Publication of JP2025521084A publication Critical patent/JP2025521084A/ja
Publication of JP2025521084A5 publication Critical patent/JP2025521084A5/ja
Pending legal-status Critical Current

Links

JP2024566249A 2022-05-10 2023-05-10 神経変性疾患における制御されたタンパク質分解のための組成物及び方法 Pending JP2025521084A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263340148P 2022-05-10 2022-05-10
US63/340,148 2022-05-10
PCT/US2023/021652 WO2023220118A2 (en) 2022-05-10 2023-05-10 Compositions and methods for controlled protein degradation in neurodegenerative disease

Publications (2)

Publication Number Publication Date
JP2025521084A JP2025521084A (ja) 2025-07-08
JP2025521084A5 true JP2025521084A5 (cg-RX-API-DMAC7.html) 2026-05-19

Family

ID=88730934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566249A Pending JP2025521084A (ja) 2022-05-10 2023-05-10 神経変性疾患における制御されたタンパク質分解のための組成物及び方法

Country Status (4)

Country Link
US (1) US20250326824A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522739A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025521084A (cg-RX-API-DMAC7.html)
WO (1) WO2023220118A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025238918A1 (ja) * 2024-05-16 2025-11-20 国立研究開発法人理化学研究所 モデルマウスおよびその作製方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595379B2 (en) * 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
CA2802349A1 (en) * 2010-06-16 2011-12-22 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Anti-dr4 agonist antibodies
CN104854133B (zh) * 2012-10-12 2018-10-30 新加坡科技研究局 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
EP3509622A4 (en) * 2016-09-08 2020-06-17 Regenerative Research Foundation BIFUNCTIONAL ANTI-TAU POLYPEPTIDES AND USE THEREOF
US11629170B2 (en) * 2016-10-12 2023-04-18 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
US11273137B2 (en) * 2018-09-04 2022-03-15 Board Of Trustees Of Michigan State University Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene

Similar Documents

Publication Publication Date Title
Ziemssen et al. Glatiramer acetate: mechanisms of action in multiple sclerosis
US20240000971A1 (en) Compositions and methods for the treatment of tauopathy
JP2024540221A (ja) Aavカプシドバリアント及びその使用
KR20190134997A (ko) 항-tau 항체 및 이의 사용 방법
AU2018248651B2 (en) Genetic construct for use in the treatment of neurodegenerative disorder or stroke
US9062125B2 (en) Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
CN114364702B (zh) 与间皮素特异性结合的抗-间皮素嵌合抗原受体
CN108350467A (zh) 基因构建体
Perche et al. Improved brain expression of anti-amyloid β scFv by complexation of mRNA including a secretion sequence with PEG-based block catiomer
US20200277350A1 (en) Proteinaceous heterodimer and use thereof
CA2698780A1 (en) Use of glp-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
CN113166777B (zh) 含有AIMP2-DX2和miR-142的靶核酸的载体及其用途
JP2009519025A5 (cg-RX-API-DMAC7.html)
US20250064855A1 (en) Use of dual-target CAR-T cells in treating B-cell autoimmune diseases
JP2023544141A (ja) AIMP2-DX2および必要に応じてmiR-142の標的配列ならびにその組成物を使用した神経系疾患を処置する方法
JP7428404B2 (ja) Gsx1を使用した脊髄損傷(sci)および脳損傷の処置
JP2021534206A5 (cg-RX-API-DMAC7.html)
US20240009285A1 (en) Compositions and Methods for Controlled Protein Degradation in Neurodegenerative Disease
JP2023540130A5 (cg-RX-API-DMAC7.html)
JP2021514961A (ja) 神経変性または神経炎症の治療または予防のための新規のil−4−/il−13−由来ペプチド化合物
US20250326824A1 (en) Compositions and methods for controlled protein degradation in neurodegenerative disease
Chiu et al. Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein
CN114805587B (zh) Car-nk细胞及其在脏器和组织老化与纤维化治疗中的用途
WO2024245132A1 (en) Optogenetic activation for signal transduction
WO2025083294A2 (en) Aat-fc fusion protein